Keywords: schering-plough, caelyx, recommended, nice, cheaper, option, topotecan
Schering-Plough's Caelyx recommended by NICE, cheaper option than topotecan
Article | 29 July 2002
Schering-Plough's anticancer agent Caelyx (pegylated liposomaldoxocrubin hydrochloride) has been recommended by the UK's National Institute for Clinical Excellence as one ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
